Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Retinal Vascular Occlusions
NCT00347711Phase 3Withdrawn
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Jun 2006
- Primary completion
- Jun 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3 trial of bevacizumab in retinal vascular occlusion (RVO) and macular edema, sponsored by Asociación para Evitar la Ceguera en México. Planned start Jun 2006; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
retinal vascular occlusion (RVO)macular edema
Beyond the preview
Go deeper on NCT00347711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00347711.